Formalin fixed, paraffin embedded human breast cancer biopsy stained with Mouse anti Human estrogen receptor beta 1 antibody (MBS214107) followed by HRP polymer detection and DAB substrate development following heat mediated antigen retrieval using citrate buffer at pH6.2 (high power)

Published customer image: Expression of PR paralleled that of ERa not ERbeta. A. Expression of PR mRNA was significantly higher in cancers that were classified as well or moderately differentiated as compared with those with a poorly differentiated phenotype (p < 0.05, n = 10 cancers in each group, comparisons indicated by letters a, b). B. PR mRNA was significantly higher in Ishikawa A [ERa-positive] compared to Ishikawa B [ERa-negative] after incubation with E2 for 16 (a) or 24 (b) hours (p < 0.01). Values are expressed as mean +/- SD of three independent experiments performed in duplicate. C. Fluorescent co-localisation as carried out using antibodies specific for ERa or ERbeta1 (both green) and PR (red). The cancers illustrated were classified as well (code 1614), moderately (code 1930) or poorly (c, codes 0001 and 1176) differentiated; at least 8 samples were analysed in each group. Co-expression was detected as yellow/orange immunofluoresence. In the well and moderately differentiated cancers expression of PR was most intense in epithelial cells and broadly overlapped with that of ERa (e.g. in cells indicated by arrows). Expression of PR was very low in the poorly differentiated cancers and appeared confined to cells with a fibroblast phenotype (**). Some ERbeta1 positive cells were PR positive however most cells in the poorly differentiated cancers were ERbeta1 positive and PR negative (green nuclei). Labels: L = lumen, S = stromal compartment, arrowheads = ERbeta1 postive cells that are PR negative.From: Collins F, MacPherson S, Brown P, Bombail V, Williams AR, Anderson RA, Jabbour HN, Saunders PT. Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalpha. BMC Cancer. 2009 Sep 16;9:330.

Staining of paraffin embedded human breast cancer tissue with Mouse anti Human estrogen receptor following antigen retrieval with EDTA. Detection was performed with Histar detection kit (MBS239184)

Staining of formalin fixed, paraffin embedded human placenta with Mouse anti Human estrogen receptor (MBS214107)

Published customer image: Immunoexpression of ERs in endometrial cancers. Tissues were classified as well (A-D), moderately (E-H) or poorly (J-M) differentiated; main panels show closely adjacent sections from three cancer blocks to allow direct comparisons. All proteins were immunolocalised to cell nuclei (see higher power inserts in panels e, f, c and d respectively). In the well and moderately differentiated cancers expression was most intense in epithelial cell layers (arrowheads, panel A and inserts). Note that ERa was low/absent in poor grade cancers (J) but immunoexpression of ERbeta1, 2, 5 was readily detected (K. L, M). Inserts in panels K, L, and M show negative controls for ERbeta1, ERbeta2 and ERbeta5 antibodies respectively generated using primary antibodies pre-absorbed with specific peptides used for immunisation. Asterisks (*) label the stromal compartment that was well defined in the well differentiated cancers.From: Collins F, MacPherson S, Brown P, Bombail V, Williams AR, Anderson RA, Jabbour HN, Saunders PT. Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalpha. BMC Cancer. 2009 Sep 16;9:330.

Staining of paraffin embedded human breast cancer tissue with Mouse anti Human estrogen receptor (MBS214107) following antigen retrieval with EDTA. Detection was performed with Histar detection kit (MBS239184)

Staining of formalin fixed, paraffin embedded human placenta with Mouse anti Human estrogen receptor (MBS214107)

Photomicrograph of human ovary immunostained for estrogen receptor beta using monoclonal antibody MBS215425